drugset / Trial / NCT01021215

Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers

NCT01021215

Phase 1/2 Completed 84 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupOpen-labelPrevention

Summary

The goal of this clinical research study is to learn how zileuton alone or the combination of zileuton and celecoxib may affect certain chemicals in the body that may be linked with a risk for smoking-related lung disease. These effects will be measured by a urine test

Timeline

Start
2010-05
Primary completion
2012-08
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 200 mg Oral
Subject Zileuton Small molecule 1200 mg Oral

Indications